About Fibrocell Science
Fibrocell Science is a company based in Exton (United States) founded in 1995 was acquired by Castle Creek Pharma in September 2019. Fibrocell Science has raised $34.66 million across 20 funding rounds from investors including Castle Creek Pharma, Precigen and EBMRF. Fibrocell Science operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Exton, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Fibrocell Science, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$34.66 M (USD)
in 20 rounds
-
Latest Funding Round
$900 K (USD), Post-IPO
Dec 20, 2018
-
Investors
Castle Creek Pharma
& 3 more
-
Employee Count
Not available
-
Acquired by
Castle Creek Pharma
(Sep 12, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Fibrocell Science
Unlock access to complete
Unlock access to complete
Funding Insights of Fibrocell Science
Fibrocell Science has successfully raised a total of $34.66M across 20 strategic funding rounds. The most recent funding activity was a Post-IPO round of $900 thousand completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Fibrocell Science
Fibrocell Science has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Castle Creek Pharma, Precigen and EBMRF.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research funding and awareness for Epidermolysis Bullosa are supported.
|
Locked | Locked | Locked | |
|
Research funding is provided to cure Epidermolysis Bullosa.
|
Locked | Locked | Locked | |
|
Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases
|
Locked | Locked | Locked |
Investor details for Fibrocell Science
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Fibrocell Science
Investment portfolio details for Fibrocell Science
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Fibrocell Science
Detailed financials for Fibrocell Science
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Fibrocell Science Comparisons
Peer comparison for Fibrocell Science
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Fibrocell Science
Fibrocell Science operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
Detailed competitors of Fibrocell Science
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Fibrocell Science
Complete news archive for Fibrocell Science
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fibrocell Science
Fibrocell Science was founded in 1995 and raised its 1st funding round 7 years after it was founded.
Fibrocell Science is headquartered in Exton, United States. It is registered at Exton, Pennsylvania, United States.
Fibrocell Science is a funded company, having raised a total of $34.66M across 20 funding rounds to date.
Fibrocell Science was founded in 1995 and is headquartered in Exton, United States. Autologous cell and gene therapies are developed by the company for conditions affecting the skin, connective tissue, and joints. The lead product candidate, FCX-007, targets linear scleroderma through gene therapy. Additional candidates for arthritis treatments are under development in the biotechnology sector.
Fibrocell Science's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Fibrocell Science has 4 investors. Key investors include Castle Creek Pharma, Precigen, EBMRF, and EB Research Partnership.